Ainos, Inc. reports developments tied to its transition toward AI-powered scent intelligence and industrial sensing. The company centers its commercial focus on AI Nose, an electronic olfaction platform that uses sensor arrays and proprietary artificial intelligence models, including its Smell Language Model, to convert volatile organic compound and scent signals into machine-readable Smell ID data.
Recurring news themes include AI Nose commercialization across semiconductor manufacturing, robotics, smart infrastructure, and healthcare-related environments; distribution and deployment relationships; industry classification updates; and financial results connected to the platform. Ainos also maintains a therapeutic-development program around VELDONA, a low-dose oral interferon program targeting rare, autoimmune, and infectious diseases.
Ainos (NASDAQ:AIMD), a Smell AI company, announced that Zacks Small-Cap Research published an article on its new healthcare infrastructure study at National Taiwan University Hospital (NTUH). The study deploys AI Nose in a live emergency department to collect extensive environmental monitoring data.
Ainos (NASDAQ:AIMD) launched a Smell AI study at National Taiwan University Hospital’s emergency department starting June 1, 2026. AI Nose devices will monitor scent and environmental patterns to model ER overcrowding and respiratory infection risk, generating over 2,500 hours of data in about six months.
The IRB-approved, non-invasive study collects no images, audio, or personal data and deploys sensors across waiting, treatment, and observation areas to build AI-driven environmental risk maps for smart hospital and public-health applications.
Ainos (NASDAQ:AIMD) highlighted a VASRO GmbH research update on commercialization of its AI Nose Smell AI platform. The report describes initiatives tied to about 1,400 systems for a backend semiconductor customer, 200 systems in front-end wafer fabrication qualification, and a 600-system partner commitment, supporting potential revenue generation in the second half of 2026. AI Nose deployments span backend and front-end semiconductor manufacturing, robotics integration, and healthcare infrastructure, targeting real-time environmental monitoring, predictive maintenance, and AI-driven process control.
Ainos (NASDAQ:AIMD) highlighted a Zacks Small-Cap Research report covering its AI Nose platform and Smell AI commercialization. The report describes Ainos' transition from a healthcare-focused biotech to a developer of AI-powered scent digitization technologies using Smell ID and its Smell Language Model.
According to Ainos, AI Nose targets applications in semiconductor manufacturing, robotics, smart infrastructure, and healthcare environments, and supports a SmellTech-as-a-Service model that bundles hardware deployments with software, analytics, and monitoring aimed at recurring revenue.
Ainos (NASDAQ:AIMD) reported first quarter 2026 results and updates on Smell AI commercialization. Operating expenses declined about 30% year-over-year to roughly US$2.28 million, and liquidity improved via a NT$90 million (≈US$2.8 million) financing. The company continued deploying its AI Nose platform under a roughly three-year US$2.1 million semiconductor arrangement targeting about 1,400 systems, expanded pilots in front-end chip fabs, and advanced healthcare infrastructure, robotics, and industrial use cases while growing its Smell ID datasets and Smell Language Model.
Ainos (NASDAQ:AIMD) updated its Standard Industrial Classification code from 2834 - Pharmaceutical Preparations to 3577 - Computer Peripheral Equipment, NEC, aligning with its focus on AI-powered sensing and Smell AI commercialization.
The change does not affect operations, finances, SEC reporting, Nasdaq listing, or strategy.
Ainos (NASDAQ:AIMD) announced expansion of its Smell AI deployments into healthcare infrastructure on April 17, 2026, building on existing semiconductor and robotics use cases.
Collaborations with MacKay Memorial Hospital and Topco Scientific target environmental monitoring across HVAC, power/electromechanical systems, chemical handling, and clinical labs, while the company advances its Smell ID and Smell Language Model to scale a data flywheel for repeatable deployments.
Ainos (NASDAQ:AIMD) announced a partnership with MacKay Memorial Hospital and Topco Scientific to deploy its AI Nose Smell AI platform in high-risk hospital environments starting April 2026. Initial deployment targets four core areas: power/electromechanical, gas/HVAC, chemical handling, and clinical labs including MRI suites.
The program aims to create a hospital-level environmental intelligence layer that models scent baselines, detects real-time anomalies, and supports earlier awareness of infection, chemical, and infrastructure risks while validating platform-level adoption and system integration.
Ainos (NASDAQ:AIMD) is moving from validation to execution with visible 2026 deployment momentum for its AI Nose Smell AI platform. Key metrics: 2025 revenue +499% YoY, 82.9% gross margin, ~99% revenue tied to AI Nose, a $2.1M three-year subscription for ~1,400 systems targeted Q2 2026, plus ~200 validation units and 600 committed systems, supported by $350k customer deposits and ~$2.82M in new financing.
Ainos (NASDAQ:AIMD) reported 2025 results showing ~499% revenue growth and a swing to positive gross margin of 82.9%. The company secured a New Taiwan Dollar 90 million financing (~USD $2.82M) and announced early 2026 semiconductor deployments: ~200 front-end systems and 1,400 systems under a three-year $2.1M program with deposits received and a roadmap to 20,000 systems.
Management emphasized scaled AI Nose commercial deployments, recurring Smell ID and Smell Language Model monetization, and disciplined capital allocation entering 2026.